Entergy (NYSE:ETR) reported quarterly earnings of $1.32 per share which missed the analyst consensus estimate of $1.37 by 3.65 percent. This is a 10.2 percent decrease over earnings of $1.47 per share from the same period last year.
Gossamer Bio Announces Addition Of 2 CNS-Penetrant BTK Inhibitors To Product Candidate Pipeline: GB5121 & GB7208
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and
